JSKN033 not checked

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
4 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“JSKN033 is a fixed-dose combination consisting of JSKN003 (a HER2-targeted ADC) and envafolimab (a PD-L1 inhibitor)”In the company’s words, NCT07283198 on ClinicalTrials.gov
Tested for
Recurrent or Metastatic Cervical Cancer, Non Small Cell Lung Cancer (NSCLC), Cervical Cancer, Advanced Malignant Tumors
Main trialPhase 3
“This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN033 versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and PD-1/L1 inhibitor therapy.”In the company’s words, NCT07797153 on ClinicalTrials.gov

Other drugs for Recurrent or Metastatic Cervical Cancer

All 266 drugs for Recurrent or Metastatic Cervical Cancer

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Dec 2028 JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer
Phase 2Not yet recruiting 30 Aug 2027 A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer
Phase 2Not yet recruiting Oct 2027 JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Phase 1/2Not yet recruiting 31 Dec 2026 JSKN033 in Chinese Subjects with Advanced Malignant Tumors
Phase 1/2Terminated 31 Jul 2025 JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow JSKN033

Following is part of Solo: you see every change to JSKN033 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in